Active substance
Results for the substance tralokinumab
1 result
About this active substance
Tralokinumab is a human monoclonal antibody used in the treatment of moderate-to-severe atopic dermatitis in adult patients. It works by blocking interleukin-13 (IL-13), a cytokine involved in chronic inflammation and skin barrier dysfunction characteristic of atopic dermatitis.
Tralokinumab is administered subcutaneously, usually once every two weeks, with an initial loading dose to rapidly achieve therapeutic levels. It is used either as monotherapy or in combination with topical corticosteroids.
Common side effects include injection site reactions, conjunctivitis, headache, and upper respiratory tract infections. In rare cases, severe allergic reactions or more serious infections may occur. Regular monitoring of the patient is essential to ensure the safety and efficacy of the treatment.
Tralokinumab is an innovative therapeutic option for patients with severe atopic dermatitis, contributing to reduced inflammation, symptom relief, and improved quality of life.
Tralokinumab is administered subcutaneously, usually once every two weeks, with an initial loading dose to rapidly achieve therapeutic levels. It is used either as monotherapy or in combination with topical corticosteroids.
Common side effects include injection site reactions, conjunctivitis, headache, and upper respiratory tract infections. In rare cases, severe allergic reactions or more serious infections may occur. Regular monitoring of the patient is essential to ensure the safety and efficacy of the treatment.
Tralokinumab is an innovative therapeutic option for patients with severe atopic dermatitis, contributing to reduced inflammation, symptom relief, and improved quality of life.